A biotechnology company selling a $949 blood test that it bills as a"first of its kind" to detect cancer said it incorrectly informed about 400 customers that they might have the disease.
The Menlo Park, California, company, called Grail, said it sent a form letter to some customers who had bought its Galleri test, which detects a marker for more than 50 types of cancer,"stating incorrectly that a cancer signal was detected," a company spokeswoman told CBS MoneyWatch in a statement. In a statement, PWN Health said it said the problem was due to"a misconfiguration of our patient engagement platform used to send templated communications to individuals.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: